Research Paper Volume 12, Issue 16 pp 15995—16020

Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study

class="figure-viewer-img"

Figure 2. IHC analysis of intestine, spleen and brain from control, LAB and p62-LAB treated mice. Tissue sections from duodenal mucosa, spleen and brain, specifically the hippocampal region, were stained with an anti-rodent p62 antibody (purple), an anti-human p62 antibody (purple) and an anti-Aβ(1-42) antibody (brown). Panels A1-B1, C1-D1, and E1-F1 show consecutive intestinal sections, panels A2-B2, C2-D2, and E2-F2 show consecutive spleen sections and panels A3-B3, C3-D3, and E3-F3 show consecutive brain sections. Immunohistochemical double-staining for m-p62 (arrows) and Aβ(1-42) (arrowheads) is shown (IHC, intestine and spleen 20×, scale bar = 100 μm; brain 40×, scale bar = 200 μm, *p<0.05, **p<0.01 vs C and LAB, #p<0.05 vs LAB).